The FDA has approved the combination of Opdivo (nivolumab) plus certain types of chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, and esophageal adenocarcinoma, making it the first frontline immunotherapy agent approved in this space.
Lymphoma survivor Nina Luker talks about receiving a diagnosis at age 24 and how sharing her story with nearly 200,000 supporters on social media helped her find purpose.
CURE® is looking back at the Educated Patient® Multiple Myeloma Summit, a half-day virtual event to educate, inform and connect patients with multiple myeloma to a variety of experts in the field.
Take a look back at CURE®’s Educated Patient® Lung Cancer Summit with this roundup of stories that highlight what was discussed at this half-day virtual event.